Zimmer Biomet Files for Autonomous Monogram Robot
The orthopedic device maker seeks FDA clearance for a hands-free version of its robot used in knee replacement surgery.
Updated on Nov. 20, 2026 in Robotics

Zimmer Biomet filed a 510(k) submission on Monday seeking clearance for an autonomous version of its Monogram orthopedic robot. The company acquired Monogram Technologies in 2025 for $177 million.
Why it matters
Autonomous robotic assistance in orthopedic surgery could change how total knee replacements are performed in the United States, pending FDA review. A clinical trial of the current semi-autonomous system reported no safety events.
The autonomous system is hands-free and activated by foot pedals, with automated bone cutting built into its design. The robot can be used with CT imaging and helps with faster bone preparation and landmarking.
The players
Zimmer Biomet
Zimmer Biomet is a major American medical device company specializing in orthopedic implants and surgical technologies.
Monogram Technologies
Monogram Technologies developed a semi-autonomous robotic system for orthopedic surgery before being acquired by Zimmer Biomet.
U.S. Food and Drug Administration
The FDA is the federal agency responsible for reviewing and clearing medical devices sold in the United States.
The details
Zimmer Biomet filed for 510(k) clearance on Monday for an autonomous version of its Monogram robot, which would operate without manual control during procedures. Two orthopedic surgeons discussed the new robot at a Stifel conference on Sunday, citing potential for time savings, reduced instrument tray use and better accuracy.
Timeline
2025: Zimmer acquired Monogram Technologies for $177 million.
Monday: Zimmer filed its 510(k) submission for the autonomous robot.
Sunday: Surgeons discussed the robot at a Stifel conference.
2027: Zimmer expects FDA clearance and a launch of the robot, ahead of its original 2028 plan.
Roadmap
The filing extends Monogram's existing semi-autonomous platform toward fully hands-free orthopedic surgery. It follows Zimmer Biomet's 2025 acquisition as the company moves to expand its robotic surgery offerings ahead of its original timeline.
If cleared, the autonomous robot could change how knee replacement procedures are performed, potentially affecting surgery time and instrument preparation. Patients considering total knee replacement may eventually encounter robot-assisted procedures with hands-free operation.
The takeaway
Robotic assistance in joint replacement is moving toward greater autonomy, and the FDA's decision on Zimmer's filing will signal how quickly that shift reaches U.S. operating rooms. Readers tracking medical devices can watch for the clearance announcement next year.
What happens next
The FDA's review of Zimmer's 510(k) submission is expected to conclude with a decision sometime next year, with a launch targeted for 2027.
Further reading
For related coverage, explore more Robotics developments in medical and industrial automation.
Source note: This article includes information reported by MedTech Dive.






